TetraLogic (Princeton) Expands Series C Financing with New Investor Pfizer Ventures (9/27/2010)

TetraLogic Pharmaceuticals is a Princeton spinoff that develops small molecule drugs to treat debilitating diseases and conditions

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that Pfizer Ventures has joined the syndicate of Series C investors with an investment of $5 million, increasing the amount of the Series C financing to $37 million. The initial Series C financing closing of $32 million was announced by TetraLogic Pharmaceuticals on August 10, 2010. The Series C financing was led by Clarus Ventures and included new investor Hatteras Venture Partners and existing investors Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group. [read more]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: